Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -308,994 | -197,833 | -102,998 | -349,848 | -258,295 |
| Depreciation Amortization | 19,594 | 10,586 | 4,460 | 14,703 | 10,904 |
| Accounts payable and accrued liabilities | 7,563 | 6,535 | 795 | -3,717 | -170 |
| Other Working Capital | -1,411 | -8,791 | 9,612 | -19,112 | -12,326 |
| Other Operating Activity | 36,466 | 23,321 | 13,201 | 83,555 | 57,107 |
| Operating Cash Flow | $-246,782 | $-166,182 | $-74,930 | $-274,419 | $-202,780 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -537 | -550 | -34,082 | -127,987 | 10,819 |
| PPE Investments | -59,231 | -43,296 | -27,347 | -13,065 | -2,662 |
| Purchase Of Investment | -1,000 | -1,000 | -1,000 | N/A | N/A |
| Sale Of Investment | 128,188 | 113,434 | 14,345 | 56,166 | 44,759 |
| Purchase Sale Intangibles | -21,229 | -21,229 | -21,229 | N/A | N/A |
| Other Investing Activity | -21,229 | -21,229 | -21,229 | 0 | 0 |
| Investing Cash Flow | $46,191 | $47,359 | $-69,313 | $-84,886 | $52,916 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 124,375 | N/A | N/A | 338,500 | 40,000 |
| Debt Repayment | -40 | 0 | 0 | N/A | N/A |
| Common Stock Issued | 74 | 74 | 74 | 169,991 | 142,058 |
| Other Financing Activity | -736 | -387 | -372 | -3,048 | -2,568 |
| Financing Cash Flow | $123,673 | $-313 | $-298 | $505,443 | $179,490 |
| Exchange Rate Effect | 123 | 80 | -175 | 48 | -17 |
| Beginning Cash Position | 181,280 | 181,280 | 181,280 | 35,094 | 35,094 |
| End Cash Position | 104,485 | 62,224 | 36,564 | 181,280 | 64,703 |
| Net Cash Flow | $-76,795 | $-119,056 | $-144,716 | $146,186 | $29,609 |
| Free Cash Flow | |||||
| Operating Cash Flow | -246,782 | -166,182 | -74,930 | -274,419 | -202,780 |
| Capital Expenditure | -59,231 | -43,296 | -27,347 | -33,563 | -23,160 |
| Free Cash Flow | -306,013 | -209,478 | -102,277 | -307,982 | -225,940 |